Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Ltd ( (AU:IMM) ) has provided an announcement.
Immutep Limited has announced promising results from its INSIGHT-003 trial, presented at the ESMO Congress 2025, showcasing a novel combination of eftilagimod alfa (efti) with KEYTRUDA and chemotherapy. This combination has demonstrated strong objective response rates and disease control rates in first-line non-small cell lung cancer (1L NSCLC) patients across all PD-L1 expression levels, particularly benefiting those with low and no PD-L1 expression. The trial results suggest that efti could significantly alter the treatment landscape for 1L NSCLC, providing a new standard of care and addressing the high unmet need in patients with PD-L1 expression under 50%.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company specializing in novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3) and aims to provide innovative treatment options to patients while maximizing shareholder value.
YTD Price Performance: -16.44%
Average Trading Volume: 2,551,043
Technical Sentiment Signal: Buy
Current Market Cap: A$448.9M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.